NEWS: Our Blog

Dive into the world of Resolian with our video series featuring our CEO Patrick Bennett

Jan 10, 2024 8:00:00 AM / by Resolian posted in CEO, Bioanalysis, Growth, Resolian

hs_newPatrickExplore the history that shaped Resolian and get a sneak peek into our future plans with our new video series. 

In the series of nine videos our CEO, Patrick Bennett explains the journey behind our recent rebranding and future plans in an insightful interview with Chris O'Connor from Life Science Marketing Radio.


Chapter 1 - "We Are Resolian"

Discover the journey behind our recent rebranding directly from our CEO, Patrick Bennett, in an insightful interview with Chris O'Connor from Life Science Marketing Radio.

Get ready for an exclusive look into the heart of Resolian, as we share our resolution to be one of the best laboratories globally committed to our purpose and mission in serving customers and our scientific staff.

🎬 Watch the video here: 


Chapter 2 - "One Global Organization"

Our journey into becoming a unified global entity in just 15 months has set the stage for unparalleled flexibility and efficiency. The decision to consolidate under one name allows the organization to function seamlessly as a single entity, providing clients with the flexibility to manage clinical trials across the strategically located laboratories in the US, Europe, China, and Australia.

🎬 Watch the video below.


Chapter 3 - "Empowering Global Collaboration"

The acquisition of China-based Denali Medpharma in November 2023 marks a significant leap forward in our global capabilities, particularly benefiting clients navigating the complexities of the Chinese market.

With a team of high-quality scientists, the lab brings valuable expertise, bridging the gap for companies unfamiliar with the intricacies of operations in China. Our unique advantage lies in seamless method transfers between Western pharma clients and the China lab.

🎬 Watch the video here to find out more about what the new lab in China means for our clients.

Read more about the Resolian acquisition of Denali Medpharma here: 

Chapter 4 - "Australia Lab - Accelerating Success"

The Australia lab emerges as a game-changer for clients seeking accelerated timelines and financial advantages in early-phase clinical studies. The regulatory landscape in Australia facilitates faster initiation of first-in-human studies compared to the US and Europe, supported by a network of robust clinical facilities.

Beyond speed, there is also a financial benefit to conducting trials in Australia.

Companies can claim 43.5% R&D cash refund with the Australian Government clinical trial rebate program, delivering a dual advantage in both efficiency and finance.

🎬 Watch the video here to find out more about Resolian’s Australian lab.

Chapter 5 - "Logistics Mastery for Seamless Global Operations"

Handling samples across borders involves intricate considerations, from stability to hazards. Resolian's expertise shines in navigating these complexities, particularly evident in China where HGRAC regulations pose challenges to the movement of human-based samples.

🎬 Watch the video here to find out more about Resolian’s logistics capabilities.


Chapter 6 - "Tailored Solutions for Sponsors"

Sponsors often manage a portfolio of vendors. Most want to have some larger full-service companies in their portfolio of bioanalytical vendors. Depending on the project, those full-service vendors aren’t always the right fit. Most of them are not global. A sponsor might take advantage of one component of their service but are not necessarily what you need for this specific project.

There is always a need for laboratories like Resolian that are focused on bioanalysis.

🎬 Watch the video here to find out more about Resolian’s responsiveness and flexibility.


Chapter 7 - "Diverse Analytical Prowess Unveiled"

Unlocking the depths of Resolian's analytical capabilities reveals a remarkable breadth across various specialties. While many labs excel in specific areas, each of Resolian's entities stands out for its comprehensive strength. With extensive experience ranging from immunoassay to LCMS, including small molecules, large molecules, biologics, and oligonucleotides, Resolian covers a spectrum of analytical domains.

🎬 Watch the video here to find out more about the diverse analytical skills at Resolian.


Chapter 8 - "Balancing Unity and Uniqueness"

Four bioanalytical labs, four continents.

Navigating the question of maintaining consistency, Resolian unveils a dual approach to harmonize operations seamlessly. While integration is implemented for non-scientific functions, ensuring universal policies with local modifications, the scientific operations follow a unique path of harmonization.

🎬 Watch the video here to find out more about our goal to create a familiar environment for legacy customers, facilitating flexibility between geographies.


Chapter 9 - "Unveiling the Heartbeat - Bringing Benefits to Patients!”

In this final instalment, we explore Resolian's impact on patients' experiences in clinical trials. Unlike central labs or clinical diagnostics, bioanalysis often involves unique methods, limiting optimal locations for sample analysis.

Resolian's global network, with laboratories in multiple geographies, provides our pharma clients the leverage to strategically choose where they run analyses in alignment with their clinical trials. This not only expands the options for clients but, more importantly, broadens the reach of clinical trials, benefiting a larger population of patients around the globe.


Read More

Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO

Nov 19, 2021 10:23:36 AM / by Ryan Klein posted in Leadership, Feng Li, CEO, success, Growth

WELLESLEY, MA, November 18, 2021 /PRNewswire/ -- Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, has announced an investment in Alliance Pharma (“Alliance”), a global leader in large and small molecule bioanalytical services. Headquartered in Malvern, PA., Alliance provides a full suite of discovery bioanalytical, DMPK, regulated bioanalysis, biomarker, LC-MS/MS, immunoassay, and cell and gene therapy assays. These capabilities support preclinical-through-Phase 4 studies run by a global customer base comprised of leading pharma and biotech companies.

Dave Patteson, Partner at Ampersand, stated "We are very excited to complete this investment in Alliance and partner with Founder and President Frank Li, who will remain a significant shareholder in the Company. Ampersand’s goal is to help Alliance execute an aggressive growth strategy that will expand the Company’s global reach, scientific capabilities, and operational capacity.”

Frank Li, President of Alliance, stated "We are delighted to have Ampersand invest in Alliance. Ampersand’s deep industry expertise, broad network, and capital resources will fortify Alliance Pharma’s position as a market-leading global specialty CRO."

About Alliance Pharma

Founded in 2008, Alliance is a contract research organization (CRO) that specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Alliance Pharma provides: quantitative LC-MS/MS analysis of small molecule drugs, metabolites, biomarkers, protein, peptides and oligonucleotides, as well as immunoassay of proteins and antibody drug conjugates; immunogenicity assays (anti-drug antibody screening, confirmation, titer assessment, and Nab determination): cell-based bioassays; in vitro and in vivo drug metabolism and pharmacokinetic studies.

Alliance’s mission is to build a trusted partnership with our partners & clients to support their successful drug development programs. Alliance’s business philosophy is based on a foundation of trust, professional ethics, scientific excellence and regulatory compliance.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. Additional information about Ampersand is available at

Read More

Philadelphia Business Journal- Success Stories

Sep 30, 2013 5:43:00 AM / by adminweb_1 posted in Feng Li, CEO, Philadelphia, minority owned business, success


Years in business: 6

What made you start your business?
I got the idea a long time ago. I worked in same industry as I am now. I got intensive training. I appreciate the experience I got from that company. I was working very hard at learning and thinking about starting the business. By 2006, I began doing research on how to prepare for new business.

What did you do to survive the recession?
Alliance Pharmaceuticals was started in May 2008. We spent almost $1 million, however, only made about $28,000 with three key employees that year. We stuck with our initial business plan, focused on our expertise area, spent time to build up necessary functionalities and prepare for any potential business opportunities. All three employees deferred their pay for a year to ensure the business operation.

What has made your business successful?
We firmly adhere with our business philosophy including professional ethics, scientific excellence, regulatory compliance to win clients trust. We also have maximum business flexibility to understand our clients needs to meet and exceed their expectations.

What is the hardest part of your job?
The regulatory compliance to ensure the data quality and integrity and hiring the right employees.

What advice would you give someone starting their career or looking to start a business?
Have a dream, make a plan, prepare and execute it. You also must be confident enough to be persistent.

Would your advice be any different if you were addressing a minority?
There is no difference. The principle would be the same.


Excerpt from Philadelphia Business Journal

Read More